• What is Golidocitinib?

  Golidocitinib is an oral inhibitor of the JAK/STAT signaling pathway, primarily indicated for the treatment of hematologic malignancies such as relaps···【Read More】

  Update: 2026-02-06Source: Haiou HealthViews: 77

• How Much Does Golidocitinib Cost?

  Golidocitinib, a novel Janus kinase (JAK) inhibitor, is primarily indicated for the treatment of relapsed or refractory T-cell lymphoma and other hema···【Read More】

  Update: 2026-02-06Source: Haiou HealthViews: 73

• Golidocitinib: Pricing and Related Information

  Golidocitinib is a targeted therapy indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma (rPTCL). Following the implementa···【Read More】

  Update: 2026-02-06Source: Haiou HealthViews: 73

• How Much Does a Box of Golidocitinib Capsules Cost?

  Golidocitinib Capsules are primarily indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma. Its current market price is app···【Read More】

  Update: 2026-02-06Source: Haiou HealthViews: 73

• Indications of Golidocitinib

  Golidocitinib is a highly selective JAK inhibitor, currently indicated for adult patients with relapsed or refractory peripheral T-cell lymphoma (R/R ···【Read More】

  Update: 2026-02-05Source: Haiou HealthViews: 72

• BeiGene’s BTK Inhibitor Zanubrutinib Approved for Follicular Lymphoma in China

  On May 13, 2024, BeiGene announced that zanubrutinib (Chinese brand name: 百悦泽; international brand name: BRUKINSA), its Bruton's tyrosine kinase (···【Read More】

  Update: 2026-02-05Source: Haiou HealthViews: 85

• BeiGene Announces Approval of Multiple New Registrations for百悦泽 (Zanubrutinib) in China

  On May 6, 2023, BeiGene announced that the National Medical Products Administration (NMPA) of China had approved four related registration application···【Read More】

  Update: 2026-02-05Source: Haiou HealthViews: 76

• National Medical Products Administration Approves 百悦泽 (Zanubrutinib) for the Treatment of Patients w

  On June 22, 2021, BeiGene announced that the National Medical Products Administration (NMPA) of China had granted conditional approval to 百悦泽 (zanubru···【Read More】

  Update: 2026-02-05Source: Haiou HealthViews: 83

• NMPA Approves Zanubrutinib Capsules for Market Launch

  On June 3, 2020, the National Medical Products Administration (NMPA) granted conditional approval for the marketing of Zanubrutinib Capsules (brand na···【Read More】

  Update: 2026-02-05Source: Haiou HealthViews: 76

• Under what circumstances should Zanubrutinib be stopped immediately?

  You must contact your doctor right away if severe adverse reactions or persistent discomfort occur after taking the medicine. The decision on whether ···【Read More】

  Update: 2026-02-05Source: Haiou HealthViews: 73

• Is Zanubrutinib available for mail delivery?

  Yes, Zanubrutinib can be delivered through formal mail services. A valid prescription is required for delivery. We adopt professional sealed cold-chai···【Read More】

  Update: 2026-02-05Source: Haiou HealthViews: 73

• Is it allowed to take other similar medications at the same time during Zanubrutinib treatment?

  Concomitant use of other similar medications with Zanubrutinib is not recommended, to avoid drug-drug interactions and an increased risk of adverse re···【Read More】

  Update: 2026-02-05Source: Haiou HealthViews: 72

• Can Zanubrutinib still be used if it has expired or its outer packaging is damaged?

  No, it cannot. Please go to a hospital to get a new prescription of the medicine.【Read More】

  Update: 2026-02-05Source: Haiou HealthViews: 73

• Monthly Cost of Zanubrutinib

  Zanubrutinib, a targeted therapy used to treat lymphoma, typically costs $$1,500 to$$2,000 per month. The exact cost varies depending on the dosage, r···【Read More】

  Update: 2026-02-05Source: Haiou HealthViews: 79

• Where to Buy Zanubrutinib?

  Zanubrutinib (generic name: Zanubrutinib Capsules) is a prescription anti-tumor drug primarily indicated for the treatment of specific types of lympho···【Read More】

  Update: 2026-02-05Source: Haiou HealthViews: 76